Assembly Bio, also known as Assembly Biosciences, is a biotechnology company focused on developing innovative treatments for serious viral and liver diseases. Drawing on expertise in virology and liver disease, the company pursues novel therapies intended to improve the outlook for people living with significant health challenges. Its research and development programs include clinical candidates for recurrent genital herpes, designed to offer innovation over current standard care, as well as programs targeting chronic hepatitis D, chronic hepatitis B, and cholestatic liver diseases.

Assembly Bio’s work combines scientific research with a patient-focused commitment to developing therapies that may improve quality of life and address unmet medical needs. The company also highlights clinical studies, research publications, collaborations, and access to healthcare as part of its broader activities. Through its pipeline and continued development efforts, Assembly Bio aims to advance potential treatment options for people affected by viral and liver conditions.

The company is headquartered online at assemblybio. com and shares corporate, investor, career, and sustainability information through its website